The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease
Open accessAbstract
OBJECTIVE: To compare the real-world clinical effectiveness and long-term clinical trajectory in patients with Alzheimer disease (AD) treated with combination (COMBO) therapy consisting of cholinesterase-inhibitor (CI) plus memantine (MEM) versus CI alone versus no treatment with either. METHODS: Three hundred eighty-two subjects with probable AD underwent serial clinical evaluations at a memory disorders unit. Cognition was assessed by the Information-Memory-Concentration subscale of the Blessed Dementia Scale (BDS) and function was assessed by the Weintraub Activities of Daily Living Scale (ADL) at 6-month intervals. One hundred forty-four subjects received standard care without CI or MEM (NO-RX), 122 received CI monotherapy, and 116 received COMBO therapy with CI plus MEM. Mean follow-up was 30 months (4.1 visits) and mean cumulative medication treatment time was 22.5 months. Rates of decline were analyzed using mixed-effects regression models, and Cohen's d effect sizes were calculated annually for years 1 to 4. RESULTS: Covarying for baseline scores, age, education, and duration of illness, the COMBO group had significantly lower mean annualized rates of deterioration in BDS and ADL scores compared with the CI (P<0.001; Cohen's dBDS=0.10-0.34 and dADL=0.23-0.46 at 1 to 2 y) and NO-RX groups (P<0.001; Cohen's dBDS=0.56-0.73 and dADL=0.32-0.48 at 1 to 2 y). For the COMBO group, Cohen's d effect sizes increased with treatment duration. Similar comparisons significantly favored the CI over the NO-RX group on the BDS. CONCLUSIONS: COMBO therapy slows cognitive and functional decline in AD compared with CI monotherapy and no treatment. These benefits had small-to-medium effect sizes that increased with time on treatment and were sustained for years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Longer-term prospective observational clinical patient cohort studies report reduced clinical decline in patients with AD treated at any stage.[114][115][116][117][118][119]”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [114]
In the citing paper
“Short-term (6-12 months) RCTs (level I evidence), longer-term (12-36 months) openlabel extensions of RCTs (level II or III evidence), and long-term (2 to 5-plus years) observational prospective clinical cohort effectiveness studies (level II evidence) support the safety and benefits of anti-AD treatments in combination, most frequently as memantine added on to a stable regimen of background ChEI”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Everitt, B. S. (2001) · Psychology Press eBooks · doi:10.4324/9781410605542-11 · Cited by 6,877
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Akaike's Information Criterion in Generalized Estimating Equations
Pan, W. (2001) · Biometrics · doi:10.1111/j.0006-341x.2001.00120.x · Cited by 2,545
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Generalized Estimating Equations
Hardin, J. W., & Hilbe, J. M. (2002) · doi:10.1201/9781420035285 · Cited by 1,766
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P. R., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 915
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 623
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
Feldman, H., Gauthier, S. G., Hecker, J., Vellas, B. J., Subbiah, P., Whalen, E., & the Donepezil MSAD Study Investigators Group* (2001) · Neurology · doi:10.1212/wnl.57.4.613 · Cited by 600
The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1
Burns, A. S., Rossor, M. N., Hecker, J. R., Gauthier, S. G., Petit, H., Möller, H. ‐., Rogers, S. L., & Friedhoff, L. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017126 · Cited by 585
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
Godwin, M. S., Rühland, L., Casson, I., MacDonald, S., Delva, D., Birtwhistle, R., Lam, M., & Seguin, R. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-28 · Cited by 507
To: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
(2001) · Neurology · doi:10.1212/wnl.57.11.2153-a · Cited by 491
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.390 · Cited by 408
Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404
Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332
Krishnan, K., Charles, H. C., Doraiswamy, P. M., Mintzer, J. E., Weisler, R. H., Yu, X., Perdomo, C. A., Ieni, J. R., & Rogers, S. L. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.2003 · Cited by 281
Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials
Winblad, B. G., Jones, R. W., Wirth, Y., Stöffler, A., & Möbius, H. J. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000102568 · Cited by 257
Hashimoto, M., Kazui, H., Matsumoto, K., Nakano, Y., Yasuda, M., & Mori, E. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.676 · Cited by 241
Cognitive Test Performance in Detecting, Staging, and Tracking Alzheimer's Disease
Locascio, J. J., Growdon, J. H., & Corkin, S. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540350081020 · Cited by 228
Self-citationA simple and valid tool distinguished efficacy from effectiveness studies
Gartlehner, G., Hansen, R. A., Nissman, D., Lohr, K. N., & Carey, T. S. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.01.011 · Cited by 207
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Reisberg, ., Doody, R. S., Stöffler, A., Schmitt, F. A., Ferris, S. H., & Möbius, H. J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.49 · Cited by 183
Donepezil Therapy in Clinical Practice
Greenberg, S. M., Tennis, M. K., Brown, L. B., Gómez‐Isla, T., Hayden, D. L., Schoenfeld, D., Walsh, K. L., Corwin, C., Daffner, K. R., Friedman, P., et al. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.94 · Cited by 169
Self-citationBurns, A. S., & O'Brien, J. T. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106068299 · Cited by 157
Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
Rockwood, K. J. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.029074 · Cited by 134
Meta‐analysis of six‐month memantine trials in Alzheimer's disease
Doody, R. S., Tariot, P. N., Pfeiffer, E. A., Olin, J. T., & Graham, S. M. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.10.004 · Cited by 103
Functional Outcomes of Drug Treatment in Alzheimer???s Disease
Hansen, R. A., Gartlehner, G., Lohr, K. N., & Kaufer, D. (2007) · Drugs & Aging · doi:10.2165/00002512-200724020-00007 · Cited by 86
Burns, A., Gauthier, S., & Perdomo, C. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1746 · Cited by 71
The record of independent living
Weıntraub, S. (1986) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331758600100210 · Cited by 69
Treatment for Alzheimer's Disease?
Growdon, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271810 · Cited by 57
Self-citationChallenges to demonstrating disease‐modifying effects in Alzheimer's disease clinical trials
Cummings, J. L. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.07.001 · Cited by 53
Generalized Estimating Equations
Williams, J. D. (2004) · Journal of the American Statistical Association · doi:10.1198/jasa.2004.s322 · Cited by 52
An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting
Aguglia, E., Onor, M. L., Saina, M., & Maso, E. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x6273 · Cited by 52
Do cholinergic therapies have disease‐modifying effects in Alzheimer's disease?
Sabbagh, M. N., Farlow, M. R., Relkin, N. R., & Beach, T. G. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.02.001 · Cited by 48
Stern, R. G., Mohs, R. C., Bierer, L. M., Silverman, J. M., Schmeidler, J., Davidson, M., & Davis, K. L. (1992) · Psychiatry Research · doi:10.1016/0165-1781(92)90074-d · Cited by 41
Mossello, E., Tonon, E., Caleri, V., Tilli, S., Cantini, C., CAVALLINI, M. C., Bencini, F., Mecacci, R., MARINI, M., Bardelli, F., et al. (2004) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2004.04.040 · Cited by 37
Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease
Mohs, R. C., Kawas, C. H., & Carrillo, M. C. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.04.003 · Cited by 32
Bellelli, G., Lucchi, E., Minicuci, N., Rozzini, L., Bianchetti, A., Padovani, A., & Trabucchi, M. (2005) · Aging Clinical and Experimental Research · doi:10.1007/bf03337721 · Cited by 28
A Naturalistic Study of Galantamine for Alzheimer???s Disease
Brodaty, H., Woodward, M., Boundy, K. L., Barnes, N., & Allen, G. (2006) · CNS Drugs · doi:10.2165/00023210-200620110-00006 · Cited by 28
Effects of Cholinesterase Inhibitors on Behavioural Disturbances in Alzheimer???s Disease
Grimmer, T., & Kurz, A. (2006) · Drugs & Aging · doi:10.2165/00002512-200623120-00003 · Cited by 22
Tomita, N., Ootsuki, M., Maruyama, M., Matsui, T., Higuchi, M., Tsutsui, M., Seki, T., Iwasaki, K., Tamamizu, M., Sozu, T., et al. (2007) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2007.00367.x · Cited by 10
Aisen, P. S. S. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.08.004 · Cited by 9
Naturalistic Treatment of Alzheimer??s Disease with Galantamine
Brodaty, H., Woodward, M., Boundy, K. L., & Barnes, N. (2007) · CNS Drugs · doi:10.2165/00023210-200721040-00006 · Cited by 6
Knopman, D. S. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.03.010 · Cited by 6
Cited by
Sorted by citations
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
“Persistence, higher dosage (in later dementia stages), and duration of treatment are associated with better outcomes, even in those with advanced dementia.(92,95,114,115,130)”
Self-citationMultifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 573
Danysz, W., & Parsons, C. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02057.x · Cited by 500
Metadata
- Authors
- Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H.
- Affiliations
- Harvard University (US)
- Corresponding author
- Atri, Alireza
- Shaughnessy, Lynn W.
- Locascio, Joseph J.
- Growdon, John H.
- Venue
- Alzheimer Disease & Associated Disorders
- Published
- 2008-07
- Volume
- 22
- Issue
- 3
- Pages
- 209-221
- ISSN
- 0893-0341 (ISSN-L)
- PMC
- PMC2718545
- OpenAlex
- W2133239607
- Cited by
- 230
- References
- 54
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 10 · 2023: 7 · 2022: 14 · 2021: 2 · 2020: 8 · 2019: 6 · 2018: 10 · 2017: 8 · 2016: 14 · 2015: 20 · 2014: 15 · 2013: 21 · 2012: 33
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer Disease & Associated Disorders (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Massachusetts General Hospital
- National Institute on Aging (5P50AG05134, 1K23 AG27171-01, K23AG027171, P50AG005134)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, combination therapy, cholinesterase inhibitors, memantine, cognitive decline, functional decline, activities of daily living, long-term treatment effectiveness, real-world clinical outcomes, treatment duration
- MeSH terms
- Activities of Daily Living, Aged, Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Drug Therapy, Combination, Female, Humans, Male, Memantine, Time, Dopamine Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
